Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor

Journal of Cardiovascular Pharmacology
S VemulapalliE J Sybertz

Abstract

SCH 51866 is a potent and selective PDE1 and PDE5 inhibitor. The antiplatelet, antiproliferative, and hemodynamic effects of SCH 51866 were compared with those of E4021, a highly selective PDE5 inhibitor. SCH 51866 inhibited PDE1 and PDE5 isozymes with a 50% inhibitory concentration (IC50) of 70 and 60 nM, respectively. SCH 51866 and E4021 inhibited washed human platelet aggregation induced by collagen with an IC50 of 10 and 4 microM, respectively, and attenuated (p < 0.05) the adhesion of 111indium-labeled platelets to the nylon filament-injured rat aorta. The doses of SCH 51866 and E4021 that inhibited platelet adhesion caused significant increases in platelet cyclic guanosine monophosphate (cGMP; p < 0.05). SCH 51866 (1-10 mg/kg, p.o. twice daily) but not E4021 (3-30 mg/kg, p.o twice daily) inhibited neointima formation in the carotid arteries of spontaneously hypertensive rats (SHRs) subjected to balloon angioplasty. Moreover, SCH 51866 (0.3-10 mg/kg, p.o.) elicited dose-dependent reduction in blood pressure in SHRs, whereas E4021 (3-30 mg/kg, p.o.) did not affect blood pressure in SHRs. In conclusion, the data suggest that inhibition of PDE1 and PDE5 isozymes by SCH 51866 exerts antiplatelet and vascular protective effects...Continue Reading

References

Oct 1, 1990·British Journal of Pharmacology·M W RadomskiS Moncada
May 1, 1991·Journal of the American College of Cardiology·J S PowellH R Baumgartner
Apr 1, 1990·Trends in Pharmacological Sciences·J A Beavo, D H Reifsnyder
Jul 1, 1986·The Journal of Clinical Investigation·F Murad
May 1, 1986·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·M A ReidyS M Schwartz
Mar 1, 1980·Analytical Biochemistry·C Labarca, K Paigen
May 15, 1983·Thrombosis Research·M Radomski, S Moncada
Dec 1, 1994·Circulation·W J ManningP S Douglas
Oct 19, 1993·European Journal of Pharmacology·M DohiK Yoshida

❮ Previous
Next ❯

Citations

Oct 25, 2001·European Journal of Pharmacology·N HosogaiT Goto
Sep 16, 1998·Current Opinion in Chemical Biology·M J Perry, G A Higgs
Jan 11, 2012·Molecular Pharmacology·Masami Shimizu-AlbergineJoseph A Beavo
Aug 19, 2007·The FEBS Journal·Torsten R Dunkern, Armin Hatzelmann
Apr 23, 2014·Fundamental & Clinical Pharmacology·Carolina OteroJuan E Jung
Mar 16, 2001·Expert Opinion on Pharmacotherapy·J Cartledge, I Eardley
Apr 14, 2017·Journal of Medicinal Chemistry·Brian DyckAli Tabatabaei
Dec 13, 2005·Bioorganic & Medicinal Chemistry Letters·Kazuto YamazakiMasaharu Kanaoka
May 27, 2017·British Journal of Pharmacology·Morten LaursenUlf Simonsen
Feb 18, 2014·British Journal of Pharmacology·Stephen P H AlexanderUNKNOWN CGTP Collaborators
Jun 23, 1998·The Journal of Biological Chemistry·S H SoderlingJ A Beavo
Dec 13, 2005·The Biochemical Journal·Adam Lerner, Paul M Epstein
Oct 6, 2005·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Jun KoteraKenji Omori

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.